Epigenetic modifications must underlie lineage-specific differentiation as terminally differentiated cells express tissue-specific genes, but their DNA sequence is unchanged. Haematopoiesis provides a well-defined model to study epigenetic modifications during cell-fate decisions, as multipotent progenitors (MPPs) differentiate into progressively restricted myeloid or lymphoid progenitors. Although DNA methylation is critical for myeloid versus lymphoid differentiation, as demonstrated by the myeloerythroid bias in Dnmt1 hypomorphs 1 , a comprehensive DNA methylation map of haematopoietic progenitors, or of any multipotent/oligopotent lineage, does not exist. Here we examined 4.6 million CpG sites throughout the genome for MPPs, common lymphoid progenitors (CLPs), common myeloid progenitors (CMPs), granulocyte/macrophage progenitors (GMPs), and thymocyte progenitors (DN1, DN2, DN3). Marked epigenetic plasticity accompanied both lymphoid and myeloid restriction. Myeloid commitment involved less global DNA methylation than lymphoid commitment, supported functionally by myeloid skewing of progenitors following treatment with a DNA methyltransferase inhibitor. Differential DNA methylation correlated with gene expression more strongly at CpG island shores than CpG islands. Many examples of genes and pathways not previously known to be involved in choice between lymphoid/myeloid differentiation have been identified, such as Arl4c and Jdp2. Several transcription factors, including Meis1, were methylated and silenced during differentiation, indicating a role in maintaining an undifferentiated state. Additionally, epigenetic modification of modifiers of the epigenome seems to be important in haematopoietic differentiation. Our results directly demonstrate that modulation of DNA methylation occurs during lineage-specific differentiation and defines a comprehensive map of the methylation and transcriptional changes that accompany myeloid versus lymphoid fate decisions.
Epigenetic modifications must underlie lineage-specific differentiation as terminally differentiated cells express tissue-specific genes, but their DNA sequence is unchanged. Haematopoiesis provides a well-defined model to study epigenetic modifications during cell-fate decisions, as multipotent progenitors (MPPs) differentiate into progressively restricted myeloid or lymphoid progenitors. Although DNA methylation is critical for myeloid versus lymphoid differentiation, as demonstrated by the myeloerythroid bias in Dnmt1 hypomorphs 1 , a comprehensive DNA methylation map of haematopoietic progenitors, or of any multipotent/oligopotent lineage, does not exist. Here we examined 4.6 million CpG sites throughout the genome for MPPs, common lymphoid progenitors (CLPs), common myeloid progenitors (CMPs), granulocyte/macrophage progenitors (GMPs), and thymocyte progenitors (DN1, DN2, DN3). Marked epigenetic plasticity accompanied both lymphoid and myeloid restriction. Myeloid commitment involved less global DNA methylation than lymphoid commitment, supported functionally by myeloid skewing of progenitors following treatment with a DNA methyltransferase inhibitor. Differential DNA methylation correlated with gene expression more strongly at CpG island shores than CpG islands. Many examples of genes and pathways not previously known to be involved in choice between lymphoid/myeloid differentiation have been identified, such as Arl4c and Jdp2. Several transcription factors, including Meis1, were methylated and silenced during differentiation, indicating a role in maintaining an undifferentiated state. Additionally, epigenetic modification of modifiers of the epigenome seems to be important in haematopoietic differentiation. Our results directly demonstrate that modulation of DNA methylation occurs during lineage-specific differentiation and defines a comprehensive map of the methylation and transcriptional changes that accompany myeloid versus lymphoid fate decisions.
Haematopoietic stem cells (HSC) can self renew for life and differentiate into all myeloid and lymphoid blood lineages 2 (Fig. 1a ). Recent evidence indicates that DNA methylation has a direct role in regulating both HSC self-renewal and commitment to lymphoid versus myeloid fates 1, 3 . Although the frequencies of myeloid progenitors and differentiated cells were normal in Dnmt1-hypomorphic mice, lymphoid-restricted CLPs and their downstream thymic T cell progenitors (DN1, DN2 and DN3) were diminished. In the bone marrow of Dnmt1-hypomorphs, lymphoid, but not myeloid, transcripts were reduced, and promoters of two myeloerythroid genes were hypomethylated in HSCs. These observations support a critical role for DNA methylation in lymphocyte development, possibly through regulation of gene expression.
Here we have examined genome-wide methylation profiles of the mouse haematopoietic system, because it provides the first opportunity to examine differential methylation of a hierarchical progression of purified cell populations with well-characterized differentiation potentials ( Fig. 1a ). Eight populations, ranging from uncommitted MPP through oligopotent progenitors specified during myeloid versus lymphoid fate decisions, were fluorescence-activated cell sorting (FACS)-purified and subjected to comprehensive high-throughput array-based relative methylation (CHARM) analysis ( Fig. 1a and Supplementary Fig. 1 ). This approach investigated the methylation status of CpGs throughout the mouse genome using an algorithm favouring regions of higher CpG density (including all CpG islands 4 ), but without bias for CpG location relative to genes 5 . Using CHARM, we recently found that differential methylation occurs more frequently in CpG island 'shores' (regions within 2 kilobases of an island) than in CpG islands during multiple cellular differentiation processes 6, 7 . Additionally, the mRNA of each population was subjected to microarray and PCR with reverse transcription (RT-PCR) analyses to generate gene expression data. Thus, we were able to compare directly differentially methylated regions (DMRs) throughout the genome with expression levels of nearby genes for all eight populations.
This analysis revealed DMRs in numerous genes known to play a role in lymphoid or myeloid fate specification. For example, Lck, the Src family kinase member responsible for initiating signalling downstream of the T cell receptor (TCR) 8 , was transcriptionally upregulated from DN1 to DN3, consistent with its role in pre-TCR signal transduction ( Fig. 1b ). Interestingly, as Lck transcription was upregulated, CpGs in exon 1 through intron 2 were progressively demethylated ( Fig. 1b) . Similarly, myeloid specification from MPP through GMP was accompanied by transcriptional upregulation and progressive hypomethylation of Mpo, which encodes an enzyme central to the microbicidal activity of neutrophils 9 (Fig. 1c ). Additionally, Cxcr2, which encodes a chemokine receptor responsible for neutrophil chemotaxis 10 , was upregulated during myeloid commitment from CMP through GMP, while the gene was demethylated ( Supplementary Fig. 2a ).
Furthermore, Gadd45a (also known as Gadd45a), which is implicated in myeloid development 11 , was found to be concomitantly upregulated and demethylated in the CMP to GMP transition ( Supplementary  Fig. 2b ). Gadd45a can actively demethylate DNA in different model systems 12, 13 ; thus, hypomethylation of Gadd45a during myelopoiesis may promote further hypomethylation of genes regulating myeloid commitment. However, the role of Gadd45a in promoting demethylation is still controversial 14 . Taken together, these data indicate that CHARM analysis correctly identifies DMRs in known lymphoid and myeloid specifying genes, each confirmed by pyrosequencing and gene expression analysis, making it a valuable tool for identifying candidate genes important for lymphoid or myeloid fate specification.
Viewed globally, CHARM analysis revealed striking epigenetic plasticity, resulting in increased overall methylation upon lymphoid relative to myeloid commitment (Table 1 ). Most DMRs distinguishing MPP FL1 cells from CLP lost methylation during this step of early lymphoid commitment, but upon the subsequent transition to DN1, 15-fold more DMRs showed gain, as opposed to loss, of methylation. Similarly in the earliest step of myeloid commitment from MPP FL1 to CMP there were substantially more hypermethylated than hypomethylated DMRs, but nearly all DMRs showed loss of methylation on transition from CMP to GMP. Comparing DN1 to GMP, two populations similarly differentiated towards lymphoid and myeloid fates, respectively, there were eightfold more DMRs with higher-level methylation in DN1 cells, suggesting a skewing towards greater methylation in lymphoid compared to myeloid haematopoiesis. These observations might explain why Dnmt1-hypomorphic mice, which are unable to maintain CpG methylation properly, have normal myeloid, but diminished lymphoid development 1, 3 .
To test the hypothesis that reduced methylation preferentially promotes myeloid as opposed to lymphoid differentiation, we turned to an in vitro assay system that promotes both myeloid and lymphoid development 15, 16 . In the presence of 5-aza-29-deoxycytidine, the percentage of myeloid progeny increased at the expense of lymphoid progeny for MPP FL1 , CLP, DN1 and DN2, but not DN3, which remained lymphoid committed ( Supplementary Fig. 3a, b ). This myeloid skewing was most pronounced in DN1 cells, perhaps indicating that the large number of methylated DMRs in DN1 compared to CLP is critical for lymphoid specification (Table 1 ). We conclude that inhibiting DNA methylation promotes myeloid versus lymphoid specification, providing a mechanism for the myeloid skewing observed in Dnmt1 hypomorphs 1 .
Consistent with our previous studies 6, 7 , most DMRs were in CpG island shores ( Table 1 ). The exceptions were for MPP FL2 versus MPP FL1 , and MPP FL1 versus CLP, in which most DMRs were in CpG islands: interestingly, both of these transitions are involved in early differentiation. Differential DNA methylation and gene expression showed a statistically significant inverse relationship particularly at CpG island shores ( Fig. 2 and Supplementary Fig. 4 ). As the CHARM array design was targeted towards CpG density but not gene architecture per se, we also created a new array that included all promoters, and hybridized DNA from three of the groups studied earlier. Analysis showed a similar statistically significant inverse relationship between differential DNA methylation and gene expression, again particularly at CpG island shores ( Supplementary Fig. 4g, h) . Thus, CpG island shores are the regions with the most variability in DNA methylation between haematopoietic populations, and this variability correlates best with changes in gene expression. However, not LETTERS all DNA methylation changes correlated with changes in gene expression: for example, Tha1 is demethylated during lymphoid specification (see CHARM plots on http://charm.jhmi.edu/hsc), but is expressed at high levels from MPP through DN3. In converse, and as expected since there are multiple mechanisms for epigenetic regulation, we also identified lineage-specifying genes with changes in expression levels, but not in DNA methylation, such as Gata3 and Hes1 (see microarrays deposited in GEO).
Many novel genes with the potential to contribute to myeloid/ lymphoid fate specification were revealed by comparing CHARMidentified DMRs with gene expression data. For example, Arl4c, a member of the ADP-ribosylation factor family of GTP-binding proteins, was upregulated and hypomethylated in DN1-3 thymocytes (Fig. 3a) . Arl4c may have a role in vesicular transport 17 , but its role in lymphoid specification is unknown. Several other genes with DMRs indicative of a role in lymphoid development, such as Smad7, Gcnt2 and Cited2, were also identified ( Supplementary Fig. 5 ). Smad7, which negatively regulates TGF-beta signalling, is selectively upregulated and hypomethylated at the earliest stages of thymocyte development, indicating a role in promoting lymphopoiesis ( Supplementary Fig. 5a ). However, it causes myeloid lineage skewing when overexpressed in human cord blood progenitors 18 . Gcnt2 transcripts were downregulated in thymocyte progenitors, and the locus became hypermethylated progressively in DN1-3 progenitors ( Supplementary Fig. 5b ), consistent with a role for Gcnt2 in enabling the myeloid potential that is lost during final lymphoid lineage commitment at the DN3 stage 19, 20 .
Novel potential regulators of myelopoiesis were also identified. The Jdp2 locus was hypomethylated and its transcript was upregulated in CMP and GMP relative to thymocyte progenitors (Fig. 3b ). Jdp2 is thought to repress transcription by recruiting histone deacetylases and regulating nucleosome assembly 21 . Dach1 was also hypomethylated and expressed from MPP FL2 through GMP, but was silenced in CLP and DN1-3 thymocyte progenitors ( Supplementary Fig. 5d ), indicating it may contribute to myelopoiesis. Dach1 has been implicated in transcriptional repression through association with histone deacetylases and its Drosophila homologue is known to play a role in gonadal, limb and ocular development 22 . Thus, Jdp2 and Dach1 may feedback on the epigenome to control expression of tissue-specific genes, but their role in haematopoiesis remains uncharacterized.
Our analyses also revealed a set of genes that were progressively hypermethylated and transcriptionally silenced as differentiation progressed towards both myeloid and lymphoid fates, indicating a role in maintenance of a multipotent state. Meis1, 2900052L18Rik, Hlf, Hoxa9 and Prdm16 are all such candidates ( Fig. 3c and Supplementary Fig. 6 ).
Meis1 is known to be required for haematopoiesis and megakaryocyte lineage development 23 and may function cooperatively with Hoxa9 to regulate haematopoiesis 24 . Furthermore, both Hlf and Prdm16 have been implicated in haematopoiesis 25, 26 .
Lastly, epigenetic chromatin modifiers, including Hdac7 and Dnmt3b, were also differentially methylated during haematopoietic differentiation, indicating feed-forward mechanisms that could expand and lock in epigenetic programming necessary for cell fate commitment ( Fig. 3d and Supplementary Fig. 7 ). Hdac7, which encodes a histone deacetylase and represses transcription, was demethylated and upregulated in DN1-3 thymocytes (Fig. 3d ). Since Hdac7 is highly expressed in DN3 cells, which can no longer be reprogrammed towards a myeloid fate by ectopic IL-2R signalling 19 , it may actively repress genes responsible for maintaining myeloid lineage potential 19 . In contrast, Dnmt3b, a with DMRs at shores. DMRs within 2 kb of gene TSSs (black circles) were divided into two groups: Island (inside, cover, or overlap more than 50% of a CpG island), and Shores (up to 2 kb away from a CpG island). After robust multi-array average preprocessing, the log 2 ratios of the gene expression differences (from left to right) were plotted against Dp (left group minus right group). Black pluses represent random DMR-gene pairs more than 2 kb apart. Wilcoxon rank-sum tests were performed to test the null hypothesis. a, MPP FL2 versus DN3 DMRs. b, MPP FL2 versus GMP DMRs. methyltransferase responsible for de novo CpG methylation, is hypermethylated and downregulated progressively in CMPs and GMPs ( Supplementary Fig. 7 ). Dnmt3a and Dnmt3b were shown to be essential for HSC self-renewal, but their roles in lineage commitment remain inconclusive 27 . Downregulation of Dnmt3b in myeloid-committed cells could prevent new DNA methylation, helping to maintain the observed hypomethylated state associated with myelopoiesis. In addition, the upregulation of Dnmt3b in DN1 independent of DNA methylation changes might explain the marked acquisition of DNA methylation from CLP to DN1 (Table 1 ). In summary, these data provide a comprehensive map of the methylome during myeloid and lymphoid commitment from haematopoietic progenitors. To facilitate the general accessibility of the methylome for these haematopoietic progenitors, we also provide here a novel web platform with which the methylation status of any genomic locus of interest can be easily queried to output methylation plots. In addition to identifying candidate genes for further investigation, the data indicate several important themes for the epigenetics of lineage-specific differentiation. First, myelopoiesis and lymphopoiesis achieve markedly different methylation endpoints in differentiation, with lymphopoiesis depending much more heavily on the acquisition of DNA methylation marks, and myelopoiesis depending much more on their loss. Besides providing a mechanism for the proposed DNMT1-dependence of lymphopoiesis, these results may also explain the therapeutic specificity of DNA demethylating drug treatment of myelodysplasia, in which malignant cells arrested in early development may be induced to differentiate by DNA demethylation 28 . In addition, the results show a remarkable dynamic plasticity in methylation during lineage development. The changes are evocative of Waddington's illustrations of hills and valleys in the epigenetic landscape of development. We have recently proposed that development depends on dynamic stochastic variation in the epigenetic landscape in a given genetic environment 29 , and the maturation of undifferentiated progenitors to progressively more differentiated states could restrict that variation. Support for this idea is provided in an accompanying manuscript in this journal examining the epigenetic memory in iPS cells derived from fibroblasts and blood 30 . In that paper, lymphocyte-derived iPS cells cluster with CLP LETTERS but not the myeloid lineage using DNA methylation differences we identified, suggesting the existence of lymphocyte memory in these iPS cells consistent with the DNA methylation profiles described in this paper.
METHODS SUMMARY
Flow cytometry. Bone marrow cells and thymocytes were stained with monoclonal antibodies, then analysed and sorted using a FACSAria. Antibody details are provided in Methods. CHARM DNA methylation analysis. Genomic DNA was isolated from samples, fractionated, digested, purified, labelled and subjected to CHARM array analysis as described previously 7 . Details are provided in Methods. Bisulphite pyrosequencing. Genomic DNA was isolated from cells, treated with bisulphite and amplified by PCR. DNA methylation was measured by quantitative pyrosequencing. Details are provided in Methods. Affymetrix microarray expression analysis. Genome-wide gene expression analysis was performed using the Affymetrix GeneChip Mouse Genome 430 2.0 Array. Details are provided in Methods. OP9:OP9DL1 stromal co-cultures. Double sorted progenitors (50) were grown in wells containing confluent 1:1 OP9:OP9DL1 stromal cells in the presence of cytokines. At day 6, the cells in each well were stained and analysed by flow cytometry. Details are provided in Methods. Quantitative PCR. Cells were sorted into TRIzol, RNA was isolated and cDNA was synthesized. Real-time PCR was performed using SYBR Green reagents. Details are provided in Methods. DNA methylation query website. DNA methylation in any region from the CHARM array can be plotted at http://charm.jhmi.edu/hsc. Details are provided in Methods.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
